Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MDGL
MADRIGAL PHARMACEUTICALS, INC.
NASDAQ
$533.76
▼ DOWN 1.83% (-9.93)

KEY STATISTICS

Market Cap$12.33 B
52w High$615.00
52w Low$393.61
Dividend Yield—
Frequency—
P/E-41.70
Volume268.66K
Shares Out.23.10M

COMPANY

LEADERSHIP

William J. Sibold
CHIEF EXECUTIVE
William J. Sibold

COMPENSATION 2026

Salary$889,583
Stock Awards$7,558,495
Incentive Plan Pay$950,513
All Other Comp.$10,350
Total$12,214,250

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 6, 2007
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
915

PRICE TARGET

Target High$962.00
Target Low$542.00
Target Median$649.00
Target Consensus$677.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$404.17M
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2016-07-25Reverse1:35

PRICE

$533.76 ▼ DOWN 1.83% (−$9.93)
OVERLAYS
$528$532$536$5409:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM533.76

About Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com ↗

Madrigal Pharmaceuticals, a clinical-stage biopharma in Pennsylvania, develops therapies for cardiovascular, metabolic, and liver diseases, with lead candidate resmetirom in Phase III for NASH.

INDUSTRY

Biotechnology

A PRODUCT MADRIGAL PHARMACEUTICALS, INC. IS KNOWN FOR

Rezdiffra (resmetirom)
Rezdiffra (resmetirom)

Rezdiffra is the first FDA-approved once-daily oral medication for adults with MASH and moderate to advanced liver scarring, targeting the disease's underlying causes and addressing a significant unmet medical need.

COMPETITORS

COMPETITOR
LLY COMPARE
NVO COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$287.27M $458.33M ▲$311.34M ▼$364.25M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
168
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 586.9K
XBI
1.02% · 224.7K
FBT
3.07% · 168.7K
IBB
0.76% · 161.9K
SCHA
0.21% · 89.8K
QQQJ
0.60% · 13.4K
FESM
0.09% · 10.5K
BBMC
0.22% · 8.6K
LABU
0.70% · 8.2K
JHMM
0.07% · 7.5K
BBP
1.39% · 3.0K
BKMC
0.22% · 2.7K
XCHA.L
0.06% · 2.1K
IQSM
0.32% · 2.1K
RECS
0.01% · 1.5K
GURU
1.30% · 1.5K
HRTS
1.43% · 1.5K
FSCC
0.19% · 1.2K
PTL
0.07% · 1.1K
OP
OPTZ
0.24% · 1.0K
TILT
0.02% · 850
BIB
0.44% · 825
MEDI
1.01% · 817
ESUM
0.18% · 680
GUSA
0.01% · 555
WELP.L
1.55% · 440

INSTITUTIONAL OWNERSHIP

SHARES OWNED
74.81%
HOLDERS
565
TOP 12 OF 565 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
2.1M sh · $1.15B
Janus Henderson Group Plc
2.0M sh · $1.05B
Rtw Investments, LP
2.0M sh · $1.07B
Paulson & Co. Inc.
1.9M sh · $874.9M
Avoro Capital Advisors LLC
1.8M sh · $984.41M
Vanguard Group Inc
1.8M sh · $831.12M
Blackrock, Inc.
1.6M sh · $957.8M
Blackrock Inc.
1.4M sh · $399.86M
Wellington Management Group Llp
825.7K sh · $443.37M
State Street Corp
658.1K sh · $301.84M
Fmr LLC
511.7K sh · $267.87M
Citadel Advisors LLC
507.2K sh · $272.36M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-04-10

INSIDER TRADES

★
OFFICER: GENERAL COUNSEL
Kelley Shannon T
Sale · 664 shares
2026-08-17
★
DIRECTOR
REED JOHN C
Purchase · 1.1K shares
2026-08-15
★
DIRECTOR
REED JOHN C
Purchase · 647 shares
2026-08-15
★
DIRECTOR:
REED JOHN C
— · —
2026-08-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 3
OVERWEIGHT 3
NEUTRAL 1
MARKET OUTPERFORM 1
12 GRADES IN THE LAST 12 MONTHS
Wolfe Research OUTPERFORM Barclays OVERWEIGHT Canaccord Genuity BUY B of A Securities NEUTRAL Truist Securities BUY Evercore ISI Group OUTPERFORM HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
JAZZ$244.54COMPARE
EXEL$54.45COMPARE
BAX$26.13COMPARE
BMRN$64.67COMPARE
TECH$72.35COMPARE
ABVX$113.35COMPARE
RYTM$107.17COMPARE